Psoriasis Autoantigens: How LL-37 and Other Peptides Trigger Autoimmune Skin Inflammation
Four psoriasis autoantigens have been identified — including cathelicidin LL-37 — with autoreactive T cells and autoantibodies found in patients, establishing psoriasis as an autoimmune disease.
Quick Facts
What This Study Found
LL-37 and ADAMTSL5 autoantibodies are strongly associated with psoriatic arthritis, establishing psoriasis as an autoimmune disease with specific peptide autoantigens.
Key Numbers
4 autoantigens since 2014; autoreactive T cells; anti-LL-37 and anti-ADAMTSL5 antibodies linked to PsA
How They Did This
Review of published studies on psoriasis autoantigen discovery, autoreactive T cell characterization, and autoantibody association with disease subtypes.
Why This Research Matters
Identifying specific autoantigens opens the door to antigen-targeted therapies that could treat psoriasis without broadly suppressing the immune system.
The Bigger Picture
Establishing psoriasis as a true autoimmune disease with defined autoantigens could lead to tolerance-inducing therapies — essentially teaching the immune system to stop attacking these specific peptides.
What This Study Doesn't Tell Us
Review article. The relative contribution of each autoantigen to disease initiation and maintenance is still being established.
Questions This Raises
- ?Could antigen-specific immunotherapy desensitize patients to LL-37?
- ?Do autoantibody levels predict progression from psoriasis to psoriatic arthritis?
- ?Are there additional undiscovered psoriasis autoantigens?
Trust & Context
- Key Stat:
- 4 autoantigens Discovered since 2014, including cathelicidin LL-37, establishing psoriasis as an autoimmune disease
- Evidence Grade:
- Review of autoantigen discovery studies with strong immunological evidence. Autoantibody-disease associations are well-documented.
- Study Age:
- Published in 2020. Autoimmune aspects of psoriasis continue to be a major research focus.
- Original Title:
- Current knowledge on autoantigens and autoantibodies in psoriasis.
- Published In:
- Scandinavian journal of immunology, 92(4), e12945 (2020)
- Database ID:
- RPEP-05161
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is psoriasis an autoimmune disease?
Yes — this review confirms that psoriasis has defined autoantigens (LL-37, ADAMTSL5, PLA2G4D, keratin 17) against which the immune system mounts specific T cell and antibody responses. This establishes it as a true autoimmune condition, not just an inflammatory disease.
What is LL-37 and why does the body attack it?
LL-37 is cathelicidin, an antimicrobial peptide normally produced by skin cells to fight infection. In psoriasis, the immune system mistakenly recognizes LL-37 as foreign and attacks cells expressing it, driving the chronic skin inflammation seen in psoriatic plaques.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05161APA
Ten Bergen, Lisa Lynn; Petrovic, Aleksandra; Aarebrot, Anders Krogh; Appel, Silke. (2020). Current knowledge on autoantigens and autoantibodies in psoriasis.. Scandinavian journal of immunology, 92(4), e12945. https://doi.org/10.1111/sji.12945
MLA
Ten Bergen, Lisa Lynn, et al. "Current knowledge on autoantigens and autoantibodies in psoriasis.." Scandinavian journal of immunology, 2020. https://doi.org/10.1111/sji.12945
RethinkPeptides
RethinkPeptides Research Database. "Current knowledge on autoantigens and autoantibodies in psor..." RPEP-05161. Retrieved from https://rethinkpeptides.com/research/ten-2020-current-knowledge-on-autoantigens
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.